PT1585524E - Utilização de endoperóxidos no tratamento de infecções causadas por flaviviridae, incluindo os vírus da hepatite c, da diarreia viral bovina e da peste suína clássica - Google Patents
Utilização de endoperóxidos no tratamento de infecções causadas por flaviviridae, incluindo os vírus da hepatite c, da diarreia viral bovina e da peste suína clássica Download PDFInfo
- Publication number
- PT1585524E PT1585524E PT03781492T PT03781492T PT1585524E PT 1585524 E PT1585524 E PT 1585524E PT 03781492 T PT03781492 T PT 03781492T PT 03781492 T PT03781492 T PT 03781492T PT 1585524 E PT1585524 E PT 1585524E
- Authority
- PT
- Portugal
- Prior art keywords
- artemisinin
- hepatitis
- treatment
- virus
- group
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 19
- 241000710781 Flaviviridae Species 0.000 title claims description 15
- 208000015181 infectious disease Diseases 0.000 title claims description 15
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 title abstract description 23
- 241000711549 Hepacivirus C Species 0.000 title abstract description 21
- 241000710777 Classical swine fever virus Species 0.000 title description 3
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 claims abstract description 27
- 229930101531 artemisinin Natural products 0.000 claims abstract description 25
- 229960004191 artemisinin Drugs 0.000 claims abstract description 25
- 229930004725 sesquiterpene Natural products 0.000 claims abstract description 12
- 150000004354 sesquiterpene derivatives Chemical class 0.000 claims abstract description 10
- 208000005176 Hepatitis C Diseases 0.000 claims abstract description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 229940079322 interferon Drugs 0.000 claims description 9
- 229910052711 selenium Inorganic materials 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 102000014150 Interferons Human genes 0.000 claims description 8
- 108010050904 Interferons Proteins 0.000 claims description 8
- 241000283690 Bos taurus Species 0.000 claims description 6
- 241001493065 dsRNA viruses Species 0.000 claims description 5
- 208000001726 Classical Swine Fever Diseases 0.000 claims description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 15
- 229930009674 sesquiterpene lactone Natural products 0.000 abstract description 10
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 abstract description 9
- 240000006891 Artemisia vulgaris Species 0.000 abstract description 5
- 235000003261 Artemisia vulgaris Nutrition 0.000 abstract description 5
- 239000000284 extract Substances 0.000 abstract description 5
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 4
- 208000036142 Viral infection Diseases 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 230000009385 viral infection Effects 0.000 abstract description 3
- 235000003826 Artemisia Nutrition 0.000 abstract description 2
- 241000710778 Pestivirus Species 0.000 abstract description 2
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 abstract description 2
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 235000009052 artemisia Nutrition 0.000 abstract description 2
- 241001430294 unidentified retrovirus Species 0.000 abstract description 2
- 241000450599 DNA viruses Species 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 description 15
- 229960000981 artemether Drugs 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 description 14
- 229960002521 artenimol Drugs 0.000 description 10
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 description 10
- 229930016266 dihydroartemisinin Natural products 0.000 description 10
- 229960004991 artesunate Drugs 0.000 description 8
- FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 description 8
- 208000019423 liver disease Diseases 0.000 description 8
- 241000701022 Cytomegalovirus Species 0.000 description 7
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 241000700618 Vaccinia virus Species 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 241001118702 Border disease virus Species 0.000 description 5
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229960000329 ribavirin Drugs 0.000 description 5
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 5
- -1 sesquiterpene lactone compounds Chemical class 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 206010051511 Viral diarrhoea Diseases 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 235000001405 Artemisia annua Nutrition 0.000 description 3
- 240000000011 Artemisia annua Species 0.000 description 3
- 240000001851 Artemisia dracunculus Species 0.000 description 3
- 235000003092 Artemisia dracunculus Nutrition 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000003097 Artemisia absinthium Nutrition 0.000 description 2
- 240000002877 Artemisia absinthium Species 0.000 description 2
- 235000015701 Artemisia arbuscula Nutrition 0.000 description 2
- 235000002657 Artemisia tridentata Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 235000013323 absinthe Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000816 toxic dose Toxicity 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000001181 artemisia dracunculus Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000020403 chronic hepatitis C virus infection Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 230000012953 feeding on blood of other organism Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42268302P | 2002-10-31 | 2002-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1585524E true PT1585524E (pt) | 2010-10-19 |
Family
ID=32312544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT03781492T PT1585524E (pt) | 2002-10-31 | 2003-10-29 | Utilização de endoperóxidos no tratamento de infecções causadas por flaviviridae, incluindo os vírus da hepatite c, da diarreia viral bovina e da peste suína clássica |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7842719B2 (enExample) |
| EP (1) | EP1585524B1 (enExample) |
| JP (1) | JP4594734B2 (enExample) |
| CN (1) | CN100430061C (enExample) |
| AT (1) | ATE473745T1 (enExample) |
| AU (1) | AU2003287259A1 (enExample) |
| CA (1) | CA2501584C (enExample) |
| DE (1) | DE60333392D1 (enExample) |
| ES (1) | ES2348536T3 (enExample) |
| PT (1) | PT1585524E (enExample) |
| WO (1) | WO2004041176A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2353384T3 (es) | 2003-02-12 | 2011-03-01 | Georgetown University | Uso de artemisinina para tratar tumores inducidos por virus oncogénicos y para tratar infecciones víricas. |
| ES2245248B1 (es) * | 2004-06-09 | 2007-02-16 | Universidad De Salamanca | Uso de la artemisinina y sus derivados en la fabricacion de medicamentos utiles como agentes antiviricos. |
| KR100824106B1 (ko) * | 2006-05-30 | 2008-04-21 | 주식회사 씨티씨바이오 | 흰반점바이러스를 치료 또는 예방하기 위한 조성물 및 방법 |
| WO2008010620A1 (en) * | 2006-07-21 | 2008-01-24 | Ben's Lab Co., Ltd. | Composition comprising the crude drug extracts for improving liver function |
| AU2007286754A1 (en) * | 2006-08-25 | 2008-02-28 | Viropharma Incorporated | Identification and characterization of HCV replicon variants with reduced susceptibility to HCV-796, and methods related thereto |
| EP2310393A4 (en) * | 2008-06-17 | 2011-06-22 | Hhv 6 Foundation | ARTEMISININE AND DERIVATIVES THEREOF AS ANTIVIRAL AGENTS |
| CN102731464B (zh) * | 2011-04-12 | 2014-07-23 | 沈阳药科大学 | 一个倍半萜内酯化合物、制备方法及其应用 |
| WO2013006795A2 (en) | 2011-07-07 | 2013-01-10 | Humanitas International Foundation | Antiviral compositions and methods of their use |
| US20130012470A1 (en) * | 2011-07-07 | 2013-01-10 | Humanitas Technology, LLC | Antiviral compositions and methods of their use |
| US9616067B2 (en) | 2012-04-18 | 2017-04-11 | Hadasit Medical Research Services And Development Ltd. | Methods and compositions for treating viral infections |
| FR2989588A1 (fr) * | 2012-04-19 | 2013-10-25 | Centre Nat Rech Scient | Composes pour la prevention ou le traitement des infections par des virus de la famille des flaviviridae |
| CN102755316A (zh) * | 2012-07-16 | 2012-10-31 | 中国科学院武汉病毒研究所 | 青蒿素及其衍生物在制备治疗丙型肝炎病毒药物中的应用 |
| WO2018068060A1 (en) | 2016-10-07 | 2018-04-12 | Navidea Biopharmaceuticals, Inc. | Compounds and methods for diagnosis and treatment of viral infections |
| GB201805665D0 (en) * | 2018-04-05 | 2018-05-23 | Univ Nottingham | Antiviral Compounds And Methods |
| WO2019232129A1 (en) * | 2018-05-30 | 2019-12-05 | The Board Of Regents Of The University Of Texas System | Treatment of viral infections and virally associated lesions with sequiterpene lactones |
| CA3179317A1 (en) * | 2020-04-20 | 2021-10-28 | Lloyd Hung Loi TRAN | Methods for the prophylaxis and treatment of covid and covid-19 |
| CN112245424B (zh) * | 2020-10-19 | 2021-09-21 | 中国医学科学院医药生物技术研究所 | 一种没药烷倍半萜结构类似物在制备抗冠状病毒药物中的用途 |
| CN112294795B (zh) * | 2020-11-17 | 2022-03-29 | 北京化工大学 | 蒿甲醚在治疗和预防柯萨奇病毒感染中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW198722B (enExample) | 1990-05-07 | 1993-01-21 | Hoechst Ag | |
| CN1058717A (zh) | 1990-08-08 | 1992-02-19 | 中国人民解放军军事医学科学院微生物流行病研究所 | 抗疟新药—复方蒿甲醚及其制备方法 |
| CN1035767C (zh) * | 1992-11-10 | 1997-09-03 | 罗宣德 | 新的青蒿素衍生物及其用途 |
| CN1105238A (zh) * | 1992-11-10 | 1995-07-19 | 中国预防医学科学院病毒学研究所 | 抗aids病毒的药物组合物 |
| EP0713877A1 (en) | 1993-07-19 | 1996-05-29 | LUO, Xuande | Qinghaosu derivatives against aids |
| DE4447588C2 (de) | 1994-05-03 | 1997-11-20 | Omer Osama Dr Dr Med | Pflanzliches Arzneimittel zur Behandlung von chronischen und allergischen Rhino-Sino-Bronchitiden |
| CN1049435C (zh) * | 1994-11-09 | 2000-02-16 | 中国科学院上海药物研究所 | 含苯基和杂环基的青蒿素衍生物及其制备方法 |
| DE19902924A1 (de) | 1999-01-26 | 2000-08-03 | Hassan Jomaa | Verwendung von phosphororganischen Verbindungen zur prophylaktischen und therapeutischen Behandlung von Infektionen |
| CN1135974C (zh) | 2000-08-23 | 2004-01-28 | 重庆健桥医药开发有限公司 | 抗疟药新药复方双氢青蒿素 |
| JPWO2002032905A1 (ja) | 2000-10-20 | 2004-02-26 | 味の素株式会社 | マラリア治療のための医薬組成物、ドーズおよび方法 |
| ES2353384T3 (es) * | 2003-02-12 | 2011-03-01 | Georgetown University | Uso de artemisinina para tratar tumores inducidos por virus oncogénicos y para tratar infecciones víricas. |
-
2003
- 2003-09-16 US US10/664,008 patent/US7842719B2/en not_active Expired - Fee Related
- 2003-10-29 AT AT03781492T patent/ATE473745T1/de active
- 2003-10-29 JP JP2004550230A patent/JP4594734B2/ja not_active Expired - Fee Related
- 2003-10-29 DE DE60333392T patent/DE60333392D1/de not_active Expired - Lifetime
- 2003-10-29 AU AU2003287259A patent/AU2003287259A1/en not_active Abandoned
- 2003-10-29 PT PT03781492T patent/PT1585524E/pt unknown
- 2003-10-29 ES ES03781492T patent/ES2348536T3/es not_active Expired - Lifetime
- 2003-10-29 CA CA002501584A patent/CA2501584C/en not_active Expired - Fee Related
- 2003-10-29 CN CNB2003801026935A patent/CN100430061C/zh not_active Expired - Fee Related
- 2003-10-29 EP EP03781492A patent/EP1585524B1/en not_active Expired - Lifetime
- 2003-10-29 WO PCT/US2003/034431 patent/WO2004041176A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ES2348536T3 (es) | 2010-12-09 |
| US7842719B2 (en) | 2010-11-30 |
| AU2003287259A8 (en) | 2004-06-07 |
| EP1585524B1 (en) | 2010-07-14 |
| CA2501584C (en) | 2009-03-10 |
| JP2006504787A (ja) | 2006-02-09 |
| WO2004041176A2 (en) | 2004-05-21 |
| CN100430061C (zh) | 2008-11-05 |
| AU2003287259A1 (en) | 2004-06-07 |
| CA2501584A1 (en) | 2004-05-21 |
| CN1711091A (zh) | 2005-12-21 |
| JP4594734B2 (ja) | 2010-12-08 |
| DE60333392D1 (de) | 2010-08-26 |
| EP1585524A2 (en) | 2005-10-19 |
| ATE473745T1 (de) | 2010-07-15 |
| WO2004041176A3 (en) | 2004-10-07 |
| US20050059647A1 (en) | 2005-03-17 |
| EP1585524A4 (en) | 2007-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2348536T3 (es) | Uso de endoperoxidos para el tratamiento de infecciones causadas por flaviviridae, incluyendo el virus de la hepatitis c, de la diarrera viral bovina y de la fiebre porcina clasica. | |
| US20110206636A1 (en) | Use of Endoperoxides for the Treatment of Infections Caused by Flaviviridae, Including Hepatitis C, Bovine Viral Diarrhea and Classical Swine Fever Virus | |
| CN101932590A (zh) | 作为抗病毒剂的2＇,4＇-取代的核苷 | |
| CN112805027A (zh) | 一种抗新冠病毒感染的药物、食物与应用 | |
| EP3785718B1 (en) | Pharmaceutical composition for prevention or treatment of flavivirus infectious disease | |
| US20040028754A1 (en) | Use of phyllanthus component for the treatment or prophylaxis of infections triggered by flaviviridae | |
| ES2684396T3 (es) | Heterociclil carboxamidas para tratar enfermedades víricas | |
| CZ340399A3 (cs) | Farmaceutický prostředek | |
| KR100239878B1 (ko) | 간질환 예방 및 치료용 생약조성물 | |
| Eddy | Carbon tetrachloride poisoning: a preliminary report on the use of methionine in hepatitis | |
| KR20120112707A (ko) | 항-에이즈 제제로서 다중고리 화합물의 제약학적 용도 | |
| JPH0341030A (ja) | 抗ウイルス剤 | |
| CN120960185B (zh) | 麝香酮在制备病毒抑制剂中的应用 | |
| WO2009084732A1 (ja) | インターフェロン・リバビリン併用療法における副作用軽減剤 | |
| WO2006033453A1 (ja) | インターフェロン作用物質の活性増強剤 | |
| CN110179785B (zh) | 魏特酮在制备治疗或预防手足口病药物中的应用 | |
| WO1992016200A1 (en) | The use of hydroxamic acid derivatives to inhibit viral replication | |
| BG65190B1 (bg) | Средство за химиотерапия и химиопрофилактика на флавивирусни инфекции | |
| JPH08208502A (ja) | 抗エイズウイルス剤の効果増強剤 | |
| TW202335673A (zh) | 一種化合物tsyi-zac用於抑制登革熱病毒感染及其醫藥治療用途 | |
| FREDRICKSON | Long-Term Efficacy and Toxicity of Antiviral Agentsa | |
| Clark | Pediatrics: Human Growth Hormone | |
| UA60328C2 (uk) | Фармацевтична композиція | |
| MXPA99008690A (en) | Pharmaceutical compositions | |
| KR20140003203A (ko) | 설폰아미드계 화합물을 유효성분으로 포함하는 ｃ형 간염의 예방 또는 치료용 약학적 조성물 |